Gensight BiologicsGSGTF FCF Yield % is -48.83 as of Jun. 30, 2026. The stock has 8 warning signs investors should review. Among 1,415 Biotechnology companies, Gensight Biologics ranks worse than 82.9% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Gensight Biologics FCF Yield % Related Terms
Gensight Biologics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Gensight Biologics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gensight Biologics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gensight Biologics (GSGTF) has a FCF Yield % of -48.83 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Gensight Biologics and its competitors. According to the industry distribution chart, Gensight Biologics ranks #1173 out of 1415 companies in the Biotechnology industry, placing it in the top 82.9%.
Is Gensight Biologics' FCF Yield % too high?
Gensight Biologics' current FCF Yield % is -48.83. Based on the distribution chart, Gensight Biologics ranks #1173 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Gensight Biologics' FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #1173 out of 1415 companies for FCF Yield %. This places Gensight Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current FCF Yield % is -48.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.09 — trading 125% above its estimated fair value. The current FCF Yield % is -48.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current FCF Yield % is -48.83 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GSGTF has been successfully added to your 